GlassScriptPhysician profile
Aya E Musa
NPI 1396199188
$1,884.87
in general payments reported to CMS, 2019-2025
24 companies · $23.26 in 2025
The $23.26 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.23 · 2020: $57.67 · 2022: $616 · 2023: $689 · 2024: $447 · 2025: $23.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $564.71 | 2020-2024 | Zepbound, Jardiance, Mounjaro |
| Abbott Laboratories | $241.92 | 2022-2025 | Freestyle Libre 3 |
| Insulet Corporation | $200.46 | 2022-2024 | Omnipod |
| Dexcom, INC. | $135.49 | 2022-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $104.97 | 2022-2023 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $77.86 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $63.03 | 2019-2022 | |
| Novo Nordisk INC | $55.84 | 2022-2023 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $53.42 | 2022 | |
| Amneal Pharmaceuticals LLC | $46.81 | 2023 | Unithroid |
| Embecta Corp. | $40.77 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Cequr Corporation | $35.50 | 2023-2024 | Cequr Simplicity |
| Medtronic, INC. | $33.11 | 2022-2023 | Minimed 780g |
| Horizon Therapeutics Plc | $30.06 | 2022 | |
| Tandem Diabetes Care, INC. | $27.55 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $24.87 | 2023 | |
| Eisai INC. | $23.25 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.57 | 2022 | |
| Pfizer INC. | $20.81 | 2022 | |
| Recordati_rare_diseases_inc. | $20.14 | 2023 | Signifor Lar, Isturisa |
| Halozyme INC | $17.11 | 2023 | |
| Alexion Pharmaceuticals, INC. | $16.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.96 | 2020 | |
| Amgen INC. | $12.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aya Musa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.